Jiangxi Youwei Biotechnology Co., Ltd.

Beijing Meiliantaike Biotechnology Co., Ltd. was established in July 2017, with dual R&D centers in California, USA and Beijing, China. It is a modern biotechnology company dedicated to the in vitro diagnostics field, integrating R&D, production, sales, and service. The company possesses complete independent intellectual property rights and a systematic product portfolio of instruments and reagents, covering pathological diagnosis and immunoassay diagnosis.
The fully automated immunohistochemistry staining system developed and produced by Beijing Meiliantaike Biotechnology Co., Ltd. is suitable for pathological diagnosis testing required for precision medicine, and is widely applicable to pathology departments of major hospitals and independent testing centers. Meanwhile, the immunoassay diagnostic system developed and produced adopts magnetic microparticle separation technology, with advantages such as strong capture capability, fast separation speed, and high sensitivity in the reaction process, representing the current mainstream international immunoassay technology. The MS series fully automated immunoassay analyzers based on microparticle separation technology meet the needs of China's hierarchical diagnosis and treatment, and are widely applicable to laboratories, emergency departments, cardiology departments, cardiac surgery departments, and other departments at hospitals of all levels. Among them, the MS-Fast instrument adopts independently packaged single-item testing, making it particularly suitable for rapid testing projects and the immunoassay diagnostic needs of numerous mid-to-low-end hospitals.
Beijing Meiliantaike Biotechnology Co., Ltd. adheres to the cultural philosophy of "virtue first, win by quality" and abides by the corporate philosophy of "strict self-discipline, proactive progress, and integrity-based." It provides consumers with *safe and *scientific biotechnology products. Beijing Meiliantaike Biotechnology Co., Ltd. has a high starting point and develops rapidly. Looking to the future, it strives unremittingly toward the goal of becoming a first-class biotechnology company in the IVD field.